Versiti Partners with Velico to Advance Blood Health Solutions
Versiti Collaborates with Velico on Blood Center Education Program
Versiti, Inc., a national leader in blood health solutions, is excited to join forces with Velico, a pioneer in spray dried plasma manufacturing technology, through the Blood Center Education Program (BCEP). This collaboration aims to achieve a common goal of improving patient outcomes by leveraging cutting-edge technology in blood health.
Understanding the Blood Center Education Program
The BCEP is designed to provide strategic partnerships for blood centers, offering them the opportunity to gain practical experience using Velico's FrontlineODP™ system for spray drying plasma. This program not only allows participants to assess the technology's operational viability but also encourages them to provide valuable feedback on its commissioning and effective usage.
The Importance of Spray Dried Plasma
In emergency medical situations, the availability of plasma is crucial. The FrontlineODP™ system represents an innovative solution for creating spray dried plasma quickly, thus enhancing its availability precisely when and where it is required the most. This technology revolutionizes plasma storage and distribution, providing advantages such as expedited rehydration, extended shelf life, simplified transportation, and minimized product wastage.
Leadership Insights on the Collaboration
"This partnership exemplifies our mutual commitment to saving lives through advancements in blood product technology," shares Richard Meehan, President, and CEO of Velico. Both organizations share a profound dedication to transforming blood health solutions through innovation.
Dr. Barbara Bryant, Executive Vice President and Chief Medical Officer at Versiti, adds, "Versiti has a long-standing tradition of innovation in the transfusion medicine community since 1947. Our commitment to enhancing blood-based technologies plays a pivotal role in our mission. The BCEP provides an exciting avenue to engage with new technologies that we believe will significantly benefit prehospital care providers in the future."
Funding and Development Initiatives
Velico's development initiatives are supported in part by federal funding through the Department of Health and Human Services’ Administration for Strategic Preparedness and Response. This partnership illustrates a robust commitment to advancing transfusion medicine in public health.
The FrontlineODP™ Dried Plasma System, while currently investigational, is undergoing clinical trials aimed at establishing its efficacy and approval for use both in the U.S. and internationally.
About Velico and Its Mission
Velico, Inc. is a forward-thinking medical technology company with its base in Beverly, Massachusetts. This private entity is dedicated to eradicating preventable deaths due to bleeding through the development of innovative medical solutions. Velico's team possesses extensive experience and knowledge in transfusion medicine and medical device development. The company's mission is reinforced through collaborations with trauma surgeons, military medics, first responders, and blood center leaders across various sectors.
About Versiti, Inc.
Versiti, Inc., recognized as a leader in blood health innovation, focuses on enhancing patient health and supporting healthcare partners across the nation. With a commitment to providing value-added solutions in transfusion medicine, transplantation, and blood-related diseases, Versiti strives to meet the diverse needs of its clientele. Their collective efforts aim to improve patient outcomes and optimize healthcare efficiencies nationwide.
Frequently Asked Questions
What is the Blood Center Education Program?
The Blood Center Education Program (BCEP) is a collaborative initiative between Velico and Versiti aimed at providing blood centers with practical experience using advanced plasma technology.
How does Velico's technology improve plasma usage?
Velico's FrontlineODP™ system enhances the plasma's availability by enabling rapid production and longer shelf life, ultimately leading to efficient use during medical emergencies.
Who are the leaders in the collaboration?
Richard Meehan is the President and CEO of Velico, while Dr. Barbara Bryant serves as the Executive Vice President and Chief Medical Officer at Versiti, both emphasizing their shared vision for innovation in blood health.
What funding supports Velico's initiatives?
Velico's development initiatives have received federal funding from the Department of Health and Human Services specifically for strategic preparedness and research development.
What is the current status of the FrontlineODP™ system?
The FrontlineODP™ Dried Plasma System is investigational in nature and currently undergoing clinical trials to establish its safety and efficacy before approval for commercial use.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Transforming Comfort: The Future of Automotive HVAC Systems
- Future Outlook: Small Personal Loans Market Set to Expand
- Neutrinos Launches Intelligent Automation Solution for Insurers
- Hargreave Hale AIM VCT Takes Significant Step with Share Purchases
- Wendel Strengthens Educational Presence with Globeducate Stake
- ObvioHealth Appoints Richard Watkins as New Chief Revenue Officer
- MDB Capital and TCA Venture Group Join Forces to Empower Investors
- Discover the Culinary World with Eater's New App Launch
- Understanding Investor Sentiment for United Rentals Stock
- Celebrating Excellence: The Latest Winners of Top Workplaces Awards
Recent Articles
- OKYO Pharma Unveils Phase 2 Trial Recruitment for Ocular Pain Relief
- Georgia-Pacific Building Products Rejoins EIFS Industry Association
- BioLineRx Strengthens Market Position with New Cancer Drug Patent
- Techem's Impressive ESG Risk Rating Positions Them for Success
- Freeport McMoRan Adjusts Copper Sales Amid Production Setbacks
- Bystronic AG's Strategic Response to 2024 Sales Decline
- Synchrony Financial Achieves Impressive Earnings Performance
- Formycon's FYB206: A Promising Biosimilar for Keytruda
- Key Insights for Q3 Earnings Season in European Markets
- U.S. Bancorp Surprises with Strong Earnings Despite Revenue Dip
- British American Tobacco Set to Introduce Synthetic Nicotine Pouches
- Citizens Financial Group Reports Earnings Amid Revenue Challenges
- Strategic Stock Moves: Buy Occidental and Microsoft, Sell DG
- Pharvaris to Showcase Deucrictibant Research at Leading Conferences
- Elon Musk's Campaign Talks in Pennsylvania Emphasize Free Speech
- Sagimet Biosciences' Key Presentations at Liver Meeting 2024
- Opthea Announces Annual General Meeting and Leadership Changes
- Apellis to Showcase VALIANT Study Insights at ASN Kidney Week
- Discovering Top-Rated Stocks: First Solar and Clearway Energy
- Orally Disintegrating Tablets Set for Remarkable Growth Ahead
- Qualcomm's Strategic Decision: Waiting for Post-Election Insights
- Hydreight Technologies Reports Impressive Growth and Revenue Surge
- Introducing ECOTRIA CLARO 300: A New Era in Sustainable Packaging
- Green Ammo Secures Vital Defense Contracts Amid Shortages
- Perspective Therapeutics Enhances Production Capabilities
- Main Street Capital Solidifies Position with New $41.4 Million Deal
- Scilex Holding Explores Strategies for Enhancing Subsidiary Value
- Gyrodyne Celebrates Legal Victory for Flowerfield Development
- B. Riley Financial Announces Cash Dividends for Preferred Stock
- Apellis Presents Findings on Pegcetacoplan at ASN Kidney Week
- EyePoint Pharmaceuticals Expands Staff with Inducement Grants
- Criteo Set to Reveal Third Quarter Financial Insights
- Innovative Biotech Company Apogee Therapeutics to Showcase New Data
- CLN-978's FDA Clearance Marks a New Era for Autoimmune Treatment
- Square Honors Canadian Businesses Among Global Leaders
- Ardagh Metal Packaging's Strategic Move into Renewable Energy
- Invivyd Showcases PEMGARDA™ Advances at IDWeek 2024
- Freightos Achieves Milestones in Q3 with Outstanding Growth
- CI Global Asset Management Highlights October 2024 ETF Distributions
- Invivyd Set to Showcase PEMGARDA™ Findings at Upcoming Event
- Enthusiast Gaming's Smash Bros Event Draws Record Online Viewers
- Harris Poll Launches Canada Ranking of Corporate Reputation
- STP Investment Services Expands Offerings with ComplianceAdvisor
- Canadian Government Announces Major Housing Initiative
- Luxury Villas Set to Transform Palm Jebel Ali Landscape
- Pivotree's Strategic Changes and Future Focus Unveiled
- Akeso Reports Promising Outcomes from Cadonilimab Study
- Discover the 2024 SCALEit® Accelerator for Business Growth
- AlphaGraphics Welcomes Don Carpenter as Senior Franchise Director
- Enerpac Earnings Report: Navigating Challenges for FY25